Supporting Information

LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins

Liis Haljasmägi, Anu Remm, Anna Pauliina Rumm, Ekaterina Krassohhina, Hanna Sein, Anu Tamm, Kai Kisand, Pärt Peterson

Methods and materials

SARS-CoV-2 (NCBI Acc # NC_045512.2) two S (S1 aa 1-680 and S2 aa 820-1211) and N (aa 2-419) gene fragments were cloned into in-house modified pNanoLuc vector, the full sequences of the vector and cloned inserts are given below. After the transfection into HEK293 cells, the cell lysates containing NanoLuc-fusion proteins were collected at 72 h and stored at -20°C.

For Western blot, the cell lysates containing NanoLuc-fusion proteins were loaded to a 10% SDS-polyacrylamide gel and subjected to gel electrophoresis (1 h at 50 V and 2 h at 100 V). Proteins were then electrotransferred to a PVDF membrane (Millipore, 0,45 μm pore diameter) for 15 min at 10 V and 1 hour at 15 V at room temperature. Non-specific binding was blocked by incubation with 5% non-fat milk in TBST (Tris-buffered saline containing 0,1% Tween-20) for 1 h at room temperature, followed by an overnight incubation at 4 °C with primary antibodies diluted in 5% non-fat milk in TBST. The following primary antibodies were used: anti-Spike1 (diluted 1:2000, GeneTex), anti-NanoLuc (diluted 1:500, Promega). The membranes were washed three times with TBST, followed by an 1 hour incubation at room temperature with HRP-labeled secondary antibodies (Jackson ImmunoResearch) diluted in 5% non-fat milk in TBST. The chemiluminescent signal was produced using the Amersham ECL Reagents (GE Healthcare) and later detected using ImageQuant™ RT ECL™ Imager (GE Healthcare).

Plasma samples were obtained from 26 COVID-19 patients (age range 33-91 years) hospitalized at the Tartu University Hospital, Estonia. The diagnosis were confirmed by PCR analysis for SARS-CoV-2 virus. In addition, we studied 26 healthy controls (age range 23-54 years) without recent infection or COVID-19 symptoms (fever or cough) for last month. The study was conducted in accordance with the Helsinki Declaration, with the approval from the Ethics Committee of the University of Tartu.

The plasma samples were incubated with lysates containing S1, S2 and N fusion protein solutions (0.5 - 1 × 10^6 luminescence units; LU) for 1 h at RT. The Protein G Sepharose beads (25 μl of 4% suspension, Creative BioMart) were added and incubated at room temperature for 1 h in 96-well microfilter plates (Merck Millipore) to capture antibodies (in 1:40 dilution) and immune complexes to the beads. After the washing to remove unbound fusion proteins, luciferase substrate was added (Nano-Glo™ Luciferase Assay Substrate, Promega), and luminescence was measured in VICTOR X Multilabel Plate Reader (PerkinElmer Life Sciences). Results are expressed as fold changes (FC) of luminescence units (LU) (FC=LU sample/average LU of 5 healthy control samples). The positive/negative discrimination level was set to the mean plus 2 standard deviations of the healthy control samples. The experiments were performed three times in three experimental replicates. Statistics was performed using unpaired Student's t-test and Pearson correlation analysis in Graphpad Prism.

The Anti-SARS-CoV-2 IgG ELISA (Euroimmun Medizinische Labordiagnostika; Cat # EI 2668-9601 G) was performed according to the manufacturer's instructions. In semi-quantitative ELISA, IgG antibodies against SARS-CoV-2 S1 protein subunit S1 were detected. Briefly, 1:101 diluted plasma samples were added to wells coated with recombinant SARS-CoV-2 antigen and incubated for 60 minutes at 37 °C. Wells were washed three times followed by the addition of HRP-conjugated anti-human IgG and subsequent incubation for 30 minutes at 37 °C. Wells were washed three times again and a chromogen solution was added. Following 30 minutes of incubation at room temperature, the reaction was stopped and the resultant absorbance was read on a microplate reader at 450 nm with reference at 620 nm. A ratio between the extinction of the sample and calibrator on plate was calculated. According to the manufacturer's recommendations, a ratio <0.8 is considered negative, ≥0.8 and <1.1 borderline, and ≥1.1 positive.

Supporting Table 1. Main characteristics, LIPS and ELISA results of each studied patient. Patient sex, age and plasma sampling day, SARS-CoV-2 antibody values in LIPS with three antigens and EUROIMMUNE ELISA assay optical density (OD) values and its ratios to controls are given.

				LIPS			ELISA	
Patient nr	**Sex (M/F)**	**Age (years)**	**Sample day**	**SP1**	**SP2**	**N**	**OD**	**Ratio**
Pat1	M	33	11	0.8	1	3.7	0.4	1.7
Pat2	F	50	14	2.4	6.7	9.1	2.4	11.6
Pat3	M	55	12	5.1	3.9	8.4	3.4	16.2
Pat4	M	56	21	6.5	4.5	7.9	3.0	14.5
Pat5	F	58	26	11	9.3	7.7	3.4	16.6
Pat6	M	60	17	4.7	8	9	3.0	14.7
Pat7	M	61	14	2	3.3	5.2	1.0	4.8
Pat8	M	63	29	1.4	15.3	7.8	2.0	9.5
Pat9	M	70	16	3.9	7.4	10.2	2.8	13.4
Pat10	M	73	18	1.3	2.7	5.2	1.1	5.4
Pat11	M	83	20	4	2.6	7.2	3.0	14.5
Pat12	F	63	15	2.3	2.7	3.8	1.9	9.4
Pat13	F	83	17	1.5	1.2	2.7	2.4	11.5
Pat14	M	73	22	3.2	1.9	4.6	3.2	15.3
Pat15	M	57	22	2.4	1	3.4	2.9	14.2
Pat16	M	58	21	2.9	2.1	4.2	2.9	13.8
Pat17	M	63	37	2	5.1	4.9	2.1	10.2
Pat18	F	62	14	1.6	2.1	3.3	2.6	12.6
Pat19	F	62	14	2.4	2.2	5.7	2.9	13.8
Pat20	M	72	13	1.3	2.2	2.7	1.0	4.8
Pat21	F	91	14	1.1	5.6	4.4	0.8	4.1
Pat22	M	65	16	4.1	5.7	5.7	3.4	16.6
Pat23	F	55	25	2.3	1.9	5.1	2.8	13.7
Pat24	M	90	8	1.9	4.6	3.4	2.6	12.8
Pat25	M	60	15	1.5	1.6	3.5	2.1	10.2
Pat26	M	42	15	2.4	2.5	3.2	3.1	14.7



Supporting Figure 1. Western blot for the detection of NanoLuc-S1, NanoLuc-S2 and NanoLuc-N fusion proteins. The cell lysates were run a single 10% polyacrylamide gel, transferred to PVDF membrane, which was cut into two after the transfer. Left side: transfected HEK293 cell lysates of NanoLuc-S1 (S1) and NanoLuc-S2 (S2) were probed with anti-Spike1 antibody (diluted 1:2000, GeneTex). Right side: transfected HEK293 cell lysates of NanoLuc-S1, NanoLuc-S2, NanoLuc-N (N) and NanoLuc were probed with anti-NanoLuc antibody (diluted 1:500, Promega). The membranes were further incubated with HRP-labeled anti-rabbit (for S1) and anti-mouse (for NanoLuc) (both from Jackson ImmunoResearch). The detected proteins are shown by asterisks. The molecular marker lanes are shown on both sides of the membrane. The anti-S1 antibody (on left side) detects NanoLuc-S1 protein as a double band at approximately 110-120 kDa. The anti-NanoLuc antibody detects NanoLuc-S1 protein at the same location albeit weaker than seen with anti-S1 antibody. NanoLuc-S2 and NanoLuc-N are seen as strong bands at 75-80kDa. NanoLuc is seen at 20kDa but also at 38-40kDa. The predicted molecular mass of the proteins without post-translational modifications are 100kDa (NanoLuc-S1), 62kDa (NanoLuc-S2) and 59kDa (NanoLuc-N).



Supporting Figure 2. Empty NanoLuc vector without SARS-CoV-2 antigens was assayed with 4 Covid-19 and 3 control plasma samples. The NanoLuc (Promega) gene was expressed in HEK293 cells. The cell lysates were incubated with plasma samples (in 1:40 dilution) and bound to Protein G Sepharose to capture antibody complexes with viral proteins. After the washing, luciferase substrate Nano-Glo™ (Promega) was added and luminescence was measured in VICTOR X multilabel reader (PerkinElmer Life Sciences). Results are expressed as fold changes (FC) of luminescence units (LU) (FC=LU sample/average LU of 3 control samples). The luminescence values were in low range in LIPS assay and similar in Covid-19 and control individuals.

pNanoLuc1 vector




```
ID   pNanoLuc1; linear; unassigned DNA; STD; UNC; 4850 BP.
SQ   Sequence 4850 BP; 1159 A; 1276 C; 1262 G; 1153 T; 0 other;
     TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG        60
     CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC CCCGCCCATT       120
     GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC ATTGACGTCA       180
     ATGGGTGGAG TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC       240
     AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA       300
     CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC       360
     CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG ACTCACGGGG       420
     ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC AAAATCAACG       480
     GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT       540
     ACGGTGGGAG GTCTATATAA GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG       600
     CCATCCACGC TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG       660
     GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA CCGCCTATAG       720
     ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGAATTA ATACGACTCA CTATAGGGAG       780
     ACAGACTGTT CCTTTCCTGG GTCTTTTCTG CAGGCACCGT CGTCGACTTA ACAGATCTCG       840
     AGCTCAAGCT TCGAATTCTC GCCACCATGA ACTCCTTCTC CACAAGCGCC TTCGGTCCAG       900
     TTGCCTTCTC CCTGGGCCTG CTCCTGGTGT TGCCTGCTGC CTTCCCTGCC CCAGTCTTCA       960
     CACTCGAAGA TTTCGTTGGG GACTGGCGAC AGACAGCCGG CTACAACCTG GACCAAGTCC      1020
     TTGAACAGGG AGGTGTGTCC AGTTTGTTTC AGAATCTCGG GGTGTCCGTA ACTCCGATCC      1080
     AAAGGATTGT CCTGAGCGGT GAAAATGGGC TGAAGATCGA CATCCATGTC ATCATCCCGT      1140
     ATGAAGGTCT GAGCGGCGAC CAAATGGGCC AGATCGAAAA AATTTTTAAG GTGGTGTACC      1200
     CTGTGGATGA TCATCACTTT AAGGTGATCC TGCACTATGG CACACTGGTA ATCGACGGGG      1260
     TTACGCCGAA CATGATCGAC TATTTCGGAC GGCCGTATGA AGGCATCGCC GTGTTCGACG      1320
     GCAAAAAGAT CACTGTAACA GGGACCCTGT GGAACGGCAA CAAAATTATC GACGAGCGCC      1380
     TGATCAACCC CGACGGCTCC CTGCTGTTCC GAGTAACCAT CAACGGAGTG ACCGGCTGGC      1440
     GGCTGTGCGA ACGCATTCTG GCGGAATTCT GCAGTCGACG GTACCGCGGG CCCGGGATCC      1500
     ACCGGGTACA AGTAAAGCGG CCGCGACTCT AGATCATAAT CAGCCATACC ACATTTGTAG      1560
     AGGTTTTACT TGCTTTAAAA AACCTCCCAC ACCTCCCCCT GAACCTGAAA CATAAAATGA      1620
     ATGCAATTGT TGTTGTTAAC TTGTTTATTG CAGCTTATAA TGGTTACAAA TAAAGCAATA      1680
     GCATCACAAA TTTCACAAAT AAAGCATTTT TTTCACTGCA TTCTAGTTGT GGTTTGTCCA      1740
     AACTCATCAA TGTATCTTAA GGCGTAAATT GTAAGCGTTA ATATTTTGTT AAAATTCGCG      1800
     TTAAATTTTT GTTAAATCAG CTCATTTTTT AACCAATAGG CCGAAATCGG CAAAATCCCT      1860
     TATAAATCAA AAGAATAGAC CGAGATAGGG TTGAGTGTTG TTCCAGTTTG GAACAAGAGT      1920
     CCACTATTAA AGAACGTGGA CTCCAACGTC AAAGGGCGAA AAACCGTCTA TCAGGGCGAT      1980
     GGCCCACTAC GTGAACCATC ACCCTAATCA AGTTTTTTGG GGTCGAGGTG CCGTAAAGCA      2040
     CTAAATCGGA ACCCTAAAGG GAGCCCCCGA TTTAGAGCTT GACGGGGAAA GCCGGCGAAC      2100
     GTGGCGAGAA AGGAAGGGAA GAAAGCGAAA GGAGCGGGCG CTAGGGCGCT GGCAAGTGTA      2160
     GCGGTCACGC TGCGCGTAAC CACCACACCC GCCGCGCTTA ATGCGCCGCT ACAGGGCGCG      2220
     TCAGGTGGCA CTTTTCGGGG AAATGTGCGC GGAACCCCTA TTTGTTTATT TTTCTAAATA      2280
     CATTCAAATA TGTATCCGCT CATGAGACAA TAACCCTGAT AAATGCTTCA ATAATATTGA      2340
```

```
AAAAGGAAGA GTCCTGAGGC GGAAAGAACC AGCTGTGGAA TGTGTGTCAG TTAGGGTGTG      2400
GAAAGTCCCC AGGCTCCCCA GCAGGCAGAA GTATGCAAAG CATGCATCTC AATTAGTCAG      2460
CAACCAGGTG TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA AGCATGCATC      2520
TCAATTAGTC AGCAACCATA GTCCCGCCCC TAACTCCGCC CATCCCGCCC CTAACTCCGC      2580
CCAGTTCCGC CCATTCTCCG CCCCATGGCT GACTAATTTT TTTTATTTAT GCAGAGGCCG      2640
AGGCCGCCTC GGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT GGAGGCCTAG      2700
GCTTTTGCAA AGATCGATCA AGAGACAGGA TGAGGATCGT TTCGCATGAT TGAACAAGAT      2760
GGATTGCACG CAGGTTCTCC GGCCGCTTGG GTGGAGAGGC TATTCGGCTA TGACTGGGCA      2820
CAACAGACAA TCGGCTGCTC TGATGCCGCC GTGTTCCGGC TGTCAGCGCA GGGGCGCCCG      2880
GTTCTTTTTG TCAAGACCGA CCTGTCCGGT GCCCTGAATG AACTGCAAGA CGAGGCAGCG      2940
CGGCTATCGT GGCTGGCCAC GACGGGCGTT CCTTGCGCAG CTGTGCTCGA CGTTGTCACT      3000
GAAGCGGGAA GGGACTGGCT GCTATTGGGC GAAGTGCCGG GGCAGGATCT CCTGTCATCT      3060
CACCTTGCTC CTGCCGAGAA AGTATCCATC ATGGCTGATG CAATGCGGCG GCTGCATACG      3120
CTTGATCCGG CTACCTGCCC ATTCGACCAC CAAGCGAAAC ATCGCATCGA GCGAGCACGT      3180
ACTCGGATGG AAGCCGGTCT TGTCGATCAG GATGATCTGG ACGAAGAGCA TCAGGGGCTC      3240
GCGCCAGCCG AACTGTTCGC CAGGCTCAAG GCGAGCATGC CCGACGGCGA GGATCTCGTC      3300
GTGACCCATG GCGATGCCTG CTTGCCGAAT ATCATGGTGG AAAATGGCCG CTTTTCTGGA      3360
TTCATCGACT GTGGCCGGCT GGGTGTGGCG GACCGCTATC AGGACATAGC GTTGGCTACC      3420
CGTGATATTG CTGAAGAGCT TGGCGGCGAA TGGGCTGACC GCTTCCTCGT GCTTTACGGT      3480
ATCGCCGCTC CCGATTCGCA GCGCATCGCC TTCTATCGCC TTCTTGACGA GTTCTTCTGA      3540
GCGGGACTCT GGGGTTCGAA ATGACCGACC AAGCGACGCC CAACCTGCCA TCACGAGATT      3600
TCGATTCCAC CGCCGCCTTC TATGAAAGGT TGGGCTTCGG AATCGTTTTC CGGGACGCCG      3660
GCTGGATGAT CCTCCAGCGC GGGGATCTCA TGCTGGAGTT CTTCGCCCAC CCTAGGGGGA      3720
GGCTAACTGA AACACGGAAG GAGACAATAC CGGAAGGAAC CCGCGCTATG ACGGCAATAA      3780
AAAGACAGAA TAAAACGCAC GGTGTTGGGT CGTTTGTTCA TAAACGCGGG GTTCGGTCCC      3840
AGGGCTGGCA CTCTGTCGAT ACCCCACCGA GACCCCATTG GGGCCAATAC GCCCGCGTTT      3900
CTTCCTTTTC CCCACCCCAC CCCCCAAGTT CGGGTGAAGG CCCAGGGCTC GCAGCCAACG      3960
TCGGGGCGGC AGGCCCTGCC ATAGCCTCAG GTTACTCATA TATACTTTAG ATTGATTTAA      4020
AACTTCATTT TTAATTTAAA AGGATCTAGG TGAAGATCCT TTTTGATAAT CTCATGACCA      4080
AAATCCCTTA ACGTGAGTTT TCGTTCCACT GAGCGTCAGA CCCCGTAGAA AAGATCAAAG      4140
GATCTTCTTG AGATCCTTTT TTTCTGCGCG TAATCTGCTG CTTGCAAACA AAAAAACCAC      4200
CGCTACCAGC GGTGGTTTGT TTGCCGGATC AAGAGCTACC AACTCTTTTT CCGAAGGTAA      4260
CTGGCTTCAG CAGAGCGCAG ATACCAAATA CTGTCCTTCT AGTGTAGCCG TAGTTAGGCC      4320
ACCACTTCAA GAACTCTGTA GCACCGCCTA CATACCTCGC TCTGCTAATC CTGTTACCAG      4380
TGGCTGCTGC CAGTGGCGAT AAGTCGTGTC TTACCGGGTT GGACTCAAGA CGATAGTTAC      4440
CGGATAAGGC GCAGCGGTCG GGCTGAACGG GGGGTTCGTG CACACAGCCC AGCTTGGAGC      4500
GAACGACCTA CACCGAACTG AGATACCTAC AGCGTGAGCT ATGAGAAAGC GCCACGCTTC      4560
CCGAAGGGAG AAAGGCGGAC AGGTATCCGG TAAGCGGCAG GGTCGGAACA GGAGAGCGCA      4620
CGAGGGAGCT TCCAGGGGGA AACGCCTGGT ATCTTTATAG TCCTGTCGGG TTTCGCCACC      4680
TCTGACTTGA GCGTCGATTT TTGTGATGCT CGTCAGGGGG GCGGAGCCTA TGGAAAAACG      4740
CCAGCAACGC GGCCTTTTTA CGGTTCCTGG CCTTTTGCTG GCCTTTTGCT CACATGTTCT      4800
TTCCTGCGTT ATCCCCTGAT TCTGTGGATA ACCGTATTAC CGCCATGCAT                 4850
//
```

Spike 1 gene fragment with BamHI and NotI restriction enzyme sites

```
ID   Spike 1 fragment; linear; unassigned DNA; 2059 BP.
SQ   Sequence 2059 BP; 482 A; 623 C; 517 G; 437 T; 0 other;
     GGATCCTAat gttcgtcttc ctggtcctgc tgcctctggt ctcctcacag tgcgtcaatc        60
     tgacaactcg gactcagctg ccacctgctt atactaatag cttcaccaga ggcgtgtact       120
     atcctgacaa ggtgtttaga agctccgtgc tgcactctac acaggatctg tttctgccat       180
     tctttagcaa cgtgacctgg ttccacgcca tccacgtgag cggcaccaat ggcacaaagc       240
     ggttcgacaa tcccgtgctg ccttttaacg atggcgtgta cttcgcctct accgagaaga       300
     gcaacatcat cagaggctgg atctttggca ccacactgga ctccaagaca cagtctctgc       360
     tgatcgtgaa caatgccacc aacgtggtca tcaaggtgtg cgagttccag ttttgtaatg       420
     atcccttcct gggcgtgtac tatcacaaga acaataagag ctggatggag tccgagttta       480
     gagtgtattc tagcgccaac aactgcacat ttgagtacgt gagccagcct ttcctgatgg       540
     acctggaggg caagcagggc aatttcaaga acctgaggga gttcgtgttt aagaatatcg       600
     acggctactt caaaatctac tctaagcaca cccccatcaa cctggtgcgc gacctgcctc       660
     agggcttcag cgccctggag cccctggtgg atctgcctat cggcatcaac atcacccggt       720
     ttcagacact gctggccctg cacagaagct acctgacacc cggcgactcc tctagcggat       780
     ggaccgccgg cgctgccgcc tactatgtgg gctacctcca gccccggacc ttcctgctga       840
     agtacaacga gaatggcacc atcacagacg cagtggattg cgccctggac cccctgagcg       900
     agacaaagtg tacactgaag tcctttaccg tggagaaggg catctatcag acatccaatt       960
     tcagggtgca gccaaccgag tctatcgtgc gctttcctaa tatcacaaac ctgtgcccat      1020
     ttggcgaggt gttcaacgca acccgcttcg ccagcgtgta cgcctggaat aggaagcgga      1080
     tcagcaactg cgtggccgac tatagcgtgc tgtacaactc cgcctctttc agcaccttta      1140
     agtgctatgg cgtgtccccc acaaagctga atgacctgtg ctttaccaac gtctacgccg      1200
     attctttcgt gatcaggggc gacgaggtgc gccagatcgc cccggccag acaggcaaga       1260
     tcgcagacta caattataag ctgccagacg atttcaccgg ctgcgtgatc gcctggaaca      1320
     gcaacaatct ggattccaaa gtgggcggca actacaatta tctgtaccgg ctgtttagaa      1380
     agagcaatct gaagcccttc gagagggaca tctctacaga aatctaccag gccggcagca      1440
     ccccttgcaa tggcgtggag ggctttaact gttatttccc actccagtcc tacggcttcc      1500
     agcccacaaa cggcgtgggc tatcagcctt accgcgtggt ggtgctgagc tttgagctgc      1560
     tgcacgcccc agcaacagtg tgcggcccca agaagtccac caatctggtg aagaacaagt      1620
     gcgtgaactt caacttcaac ggcctgaccg gcacaggcgt gctgaccgag tccaacaaga      1680
     agttcctgcc atttcagcag ttcggcaggg acatcgcaga taccacagac gccgtgcgcg      1740
     acccacagac cctggagatc ctggacatca caccctgctc tttcggcggc gtgagcgtga      1800
     tcacacccgg caccaataca agcaaccagg tggccgtgct gtatcaggac gtgaattgta      1860
     ccgaggtgcc cgtggctatc cacgccgatc agctgacccc aacatggcgg gtgtacagca      1920
     ccggctccaa cgtcttccag acaagagccg gatgcctgat cggagcagag cacgtgaaca      1980
     attcctatga gtgcgacatc ccaatcggcg ccggcatctg tgcctcttac cagacccaga      2040
     caaactctTA AGCGGCCGC                                                  2059
//
```

Spike 2 gene fragment with BamHI and NotI restriction enzyme sites

```
ID   Spike 2 fragment; linear; unassigned DNA; 1192 BP.
SQ   Sequence 1192 BP; 277 A; 363 C; 333 G; 219 T; 0 other;
     GGATCCTAct gctgttcaac aaggtgaccc tggccgatgc cggcttcatc aagcagtatg        60
     gcgattgcct gggcgacatc gcagccaggg acctgatctg cgcccagaag tttaatggcc       120
     tgaccgtgct gccacccctg ctgacagatg agatgatcgc acagtacaca agcgccctgc       180
     tggccggcac catcacatcc ggatggacct tcggcgcagg agccgccctc cagatcccct       240
     ttgccatgca gatggcctat aggttcaacg gcatcggcgt gacccagaat gtgctgtacg       300
     agaaccagaa gctgatcgcc aatcagttta actccgccat cggcaagatc caggacagcc       360
     tgtcctctac agccagcgcc ctgggcaagc tccaggatgt ggtgaatcag aacgcccagg       420
     ccctgaatac cctggtgaag cagctgagca gcaacttcgg cgccatctct agcgtgctga       480
     atgacatcct gagccggctg gacaaggtgg aggcagaggt gcagatcgac cggctgatca       540
     ccggccggct ccagagcctc cagacctatg tgacacagca gctgatcagg gccgccgaga       600
     tcagggccag cgccaatctg gcagcaacca agatgtccga gtgcgtgctg ggccagtcta       660
     agagagtgga cttttgtggc aagggctatc acctgatgtc cttccctcag tctgccccac       720
     acggcgtggt gtttctgcac gtgacctacg tgcccgccca ggagaagaac ttcaccacag       780
     cccctgccat ctgccacgat ggcaaggccc actttccaag ggagggcgtg ttcgtgtcca       840
     acggcaccca ctggtttgtg acacagcgca atttctacga gccccagatc atcaccacag       900
     acaacacctt cgtgagcggc aactgtgacg tggtcatcgg catcgtgaac aataccgtgt       960
     atgatccact ccagcccgag ctggacagct ttaaggagga gctggataag tatttcaaga      1020
     atcacacctc ccctgacgtg gatctgggcg acatcagcgg catcaatgcc tccgtggtga      1080
     acatccagaa ggagatcgac cgcctgaacg aggtggctaa gaatctgaac gagagcctga      1140
     tcgacctcca ggagctgggc aagtatgagc agtacatcaa gTAAGCGGCC GC             1192
//
```

Nucleocapsid gene fragment with BamHI and NotI restriction enzyme sites

```
ID   N gene; linear; unassigned DNA; 1273 BP.
SQ   Sequence 1273 BP; 300 A; 438 C; 336 G; 199 T; 0 other;
     GGATCCTAtc tgacaacggc cctcagaacc agcggaacgc tcctcggatc accttcggcg        60
     gcccttctga ctctaccggc tccaaccaga acggcgagag atccggagcc agatctaagc       120
     agcggagacc ccagggcctg cccaacaaca ccgcctcttg gtttaccgcc ctgacccagc       180
     acggcaagga ggacctgaag ttccccagag gccaaggggt gcccatcaac accaactcct       240
     ccccagacga ccagatcggc tactaccggc gggctaccag aagaatcaga ggcggcgacg       300
     gcaagatgaa ggacctgtcc ccacggtggt acttctacta cctcggcaca ggacctgagg       360
     ctggcctgcc ttacggagct aacaaggacg gaatcatctg ggtggctacc gagggagctc       420
     tgaacacccc taaggaccac atcggaaccc gcaaccccgc caacaacgct gctatcgtgc       480
     tgcagctgcc tcagggaaca accctgccta agggattcta cgctgaggga tctagaggag       540
     ggtctcaggc ctcttctcgc tcttcctccc gctcccgcaa ctcttctcgc aactccaccc       600
     cagggtcttc tagagggacc tctcctgcca gaatggctgg aaacggaggc gatgctgctc       660
     tggctctgct gctcctcgac cgcctcaacc agctcgagtc caagatgtct ggaaagggcc       720
     agcaacagca ggggcagaca gtgacaaaga agtctgctgc tgaagcctct aagaagcctc       780
     gccagaagcg caccgctacc aaggcttaca acgtgaccca ggccttcggg aggaggggac       840
     ctgagcagac acagggcaac ttcggggatc aggagctcat ccgccagggg acagactaca       900
     agcactggcc ccagatcgcc cagttcgccc ctagtgcctc tgccttcttc gggatgtccc       960
     gcatcgggat ggaggtgacc ccttctggga cctggctgac ctacaccggg gccatcaagc      1020
     tcgacgacaa ggaccccaac ttcaaggacc aggtcatcct cctcaacaag cacatcgacg      1080
     cctacaagac cttcccaccc accgagccca agaaggacaa gaagaagaag gctgacgaga      1140
     cccaggccct ccctcagagg cagaagaaac agcagaccgt gaccctgctg cctgctgctg      1200
     acctcgacga cttctccaag cagctccagc agtccatgtc ctctgctgac tctacccagg      1260
     ctTAAGCGGC CGC                                                         1273
//
```